EBS Emergent Biosolutions Inc.

-0.39  -1%
Previous Close 63.72
Open 66.1
Price To Book 3.34
Market Cap 3226350396
Shares 50,945,056
Volume 714,921
Short Ratio 7.29
Av. Daily Volume 404,568

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 trial initiation announced September 9, 2017. Completion due 2019.
Influenza A
Approved May 17, 2012.
Anthrax Vaccine
Approved November 24, 2015.
Anthrax Vaccine Adsorbed
Approved March 25, 2015.
Anthrax Immune Globulin Intravenous (Human) [AIGIV]
Phase 2b data due mid-2019.
End-stage renal disease
Phase 1 data released November 19, 2018 - primary endpoint met with favorable safety profile.
Zika vaccine
Phase 3 trial planned for 2019.
Anthrax vaccine

Latest News

  1. Emergent BioSolutions Inc (EBS) Files 10-K for the Fiscal Year Ended on December 31, 2018
  2. Edited Transcript of EBS earnings conference call or presentation 21-Feb-19 10:00pm GMT
  3. Emergent (EBS) Q4 Earnings, Revenues Surpass Estimates
  4. Emergent Biosolutions Inc (EBS) Q4 2018 Earnings Conference Call Transcript
  5. Emergent Biosolutions (EBS) Q4 Earnings and Revenues Surpass Estimates
  6. Emergent Biosolutions: 4Q Earnings Snapshot
  7. Emergent BioSolutions Reports Fourth Quarter and Full Year 2018 Financial Results
  8. Factors of Influence in 2019, Key Indicators and Opportunity within CVS Health, Solaris Oilfield Infrastructure, SK Telecom Co., Energizer, Emergent Biosolutions, and Quad Graphics — New Research Emphasizes Economic Growth
  9. Who Has Been Selling Emergent BioSolutions Inc. (NYSE:EBS) Shares?
  10. Earnings Preview: Emergent Biosolutions (EBS) Q4 Earnings Expected to Decline
  11. Emergent BioSolutions Announces Appointment of Seamus Mulligan to its Board of Directors
  12. See what the IHS Markit Score report has to say about Emergent Biosolutions Inc.
  13. Emergent BioSolutions to Release Fourth Quarter and Full Year 2018 Financial Results and Conduct a Conference Call on February 21, 2019
  14. Emergent BioSolutions Announces Appointment of Robert G. Kramer, Sr. to Its Board of Directors
  15. An extended shutdown could bode poorly for local biotechs
  16. MoCo economic development officials plan satellite office in Boston
  17. Emergent (EBS) Up on '19 View, Posts Preliminary '18 Results
  18. Emergent BioSolutions CEO to step down